Perioperative haemostasis with full‐length, PEGylated, recombinant factor VIII with extended half‐life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single‐arm phase III trial
Open Access
- 28 July 2019
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 25 (5) , 773-781
Abstract
Introduction: Rurioctocog alfa pegol (BAX 855, TAK‐660) is a PEGylated, full‐length, recombinant factor VIII (rFVIII) with extended half‐life developed from unmodified rFVIII (antihaemophilic factor [recombinant]).Aim: To determine the perioperative haemostatic efficacy and safety of rurioctocog alfa pegol in male previously treated patients (PTPs) with severe haemophilia A.Methods: This multicentre, single‐arm, phase III study included PTPs who were to undergo major or minor elective or minor emergency surgical, dental or other invasive procedures. Rurioctocog alfa pegol dose and frequency were individualized based on patients’ pharmacokinetic profiles for major surgeries and by rurioctocog alfa pegol incremental recovery for minor surgeries. Haemostatic efficacy was assessed using the Global Haemostatic Efficacy Assessment score.Results: Twenty‐one patients aged 16‐61 years underwent 21 major and five minor surgeries. For all 24 evaluable surgeries, overall haemostatic efficacy was rated as excellent and blood loss comparable to that expected in non‐haemophilic patients. No blood transfusions were required intraoperatively but were administered postoperatively for four surgeries in three patients. Five injury‐related postoperative bleeding episodes occurred in five patients, of which two required additional rurioctocog alfa pegol treatment. Two non‐serious adverse events of mild severity (increased ALT level and headache) were considered possibly related to rurioctocog alfa pegol. There were no deaths or treatment‐related serious adverse events. No patients developed inhibitory antibodies to FVIII or persistent IgG‐ or IgM‐binding antibodies to FVIII, PEG‐FVIII or PEG.Conclusion: Rurioctocog alfa pegol was well tolerated and effective for perioperative use in patients with haemophilia A and showed no signs of immunogenicity.Keywords
This publication has 16 references indexed in Scilit:
- Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia ABlood, 2015
- Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia ABlood, 2014
- Modern haemophilia careThe Lancet, 2012
- Past, present and future of hemophilia: a narrative reviewOrphanet Journal of Rare Diseases, 2012
- BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation.2012
- Perioperative clotting factor replacement and infection in total knee arthroplastyHaemophilia, 2011
- The Management of Cardiovascular Diseases in Patients with HemophiliaSeminars in Thrombosis and Hemostasis, 2010
- Co‐morbidities and quality of life in elderly persons with haemophiliaBritish Journal of Haematology, 2010
- Co‐morbidity in the ageing haemophilia patient: the down side of increased life expectancyHaemophilia, 2009
- Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: Efficacy and safety of Advate in previously treated patientsThrombosis and Haemostasis, 2008